BioArctic: New lecanemab-data presented at the AD/PD 2023 conference

STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and its partner Eisai has presented new findings on lecanemab (generic name, U.S. brand name: LEQEMBI)

Related Keywords

China ,Stockholm ,Sweden ,Japan ,Uppsala ,Uppsala Lan ,Swedish ,Lars Lannfelt ,Oskar Bosson ,Alzheimer Clinical Trial Consortium ,Devices Agency ,Ministry Of Health ,National Institutes Of Health ,Washington University School Of Medicine ,National Institute On ,Drug Administration ,National Medical Products Administration ,Vp Communications ,International Conference On Alzheimer ,Nasdaq ,Alzheimer Network Trials Unit ,Uppsala University ,European Medicines Agency ,Professor Lars Lannfelt ,Clinical Trials ,New England Journal ,Early Alzheimer ,Patients Treated ,Quality Of Life Results ,Double Blind Phase ,European Quality ,Zarit Burden ,Brand Name ,Biologics License Application ,Priority Review ,Prescription Drug User Fee Act ,Medical Devices Agency ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Commercialization Agreement ,Nasdaq Stockholm Large Cap ,Zarit Burden Interview ,Bioarctic ,Lecanemab ,Data ,Resented ,023 ,Conference ,